Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer

<i>Background and Objectives</i>: breast cancer remains the most common health burden affecting females worldwide. Despite developments in breast cancer diagnostic approaches and treatment strategies, the clinical management of metastatic breast cancer remains challenging. Thus, there is...

Full description

Bibliographic Details
Main Authors: Fatemah OFO Alshammari, Anas O. Satari, Ahmed S. Aljabali, Yanal S. Al-mahdy, Yasmeen J. Alabdallat, Yahya M. Al-sarayra, Mohammad A. Alkhojah, Abdel rahman M. Alwardat, Mansour Haddad, Sameeh A. Al-sarayreh, Yousef M. Al-saraireh
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/59/1/86
_version_ 1827623386074841088
author Fatemah OFO Alshammari
Anas O. Satari
Ahmed S. Aljabali
Yanal S. Al-mahdy
Yasmeen J. Alabdallat
Yahya M. Al-sarayra
Mohammad A. Alkhojah
Abdel rahman M. Alwardat
Mansour Haddad
Sameeh A. Al-sarayreh
Yousef M. Al-saraireh
author_facet Fatemah OFO Alshammari
Anas O. Satari
Ahmed S. Aljabali
Yanal S. Al-mahdy
Yasmeen J. Alabdallat
Yahya M. Al-sarayra
Mohammad A. Alkhojah
Abdel rahman M. Alwardat
Mansour Haddad
Sameeh A. Al-sarayreh
Yousef M. Al-saraireh
author_sort Fatemah OFO Alshammari
collection DOAJ
description <i>Background and Objectives</i>: breast cancer remains the most common health burden affecting females worldwide. Despite developments in breast cancer diagnostic approaches and treatment strategies, the clinical management of metastatic breast cancer remains challenging. Thus, there is a need to identify new biomarkers and novel drug targets for breast cancer diagnosis and therapy. Recently, aberrant glypican-3 (GPC3) expression in cancers has gained considerable interest in cancer research. The studies, however, have yielded contradictory results about GPC3 expression in breast cancer. Therefore, the current study aims to analyse GPC3 expression across a large panel of different breast cancer subtypes. <i>Materials and Methods</i>: GPC3 expression was immunohistochemically evaluated in 230 breast cancer patients along with eight normal tissues and its associations to clinical and demographic characteristics, as well as immunohistochemical biomarkers for breast cancer. Moreover, a public database consisting of breast cancer patients’ survival data and GPC3 gene expression information was used to assess the prognostic value of GPC3 in the survival of breast cancer patients. <i>Results</i>: GPC3 expression was only characterised in 7.5% of different histological breast cancer subtypes. None of the normal breast tissues displayed GPC3 expression. Interestingly, all cases of Paget’s disease, as well as 42.9% of intraductal and 16.7% of mucinous carcinomas were found to have GPC3 expression, where it was able to significantly discriminate Paget’s disease and intraductal carcinoma from other breast cancer subtypes. Importantly, GPC3 expression was found more often in tumours that tested positive for the expression of hormone receptors and human epidermal growth factor receptor 2 (HER2), indicating more favourable histological subtypes of breast cancer. Consequently, longer relapse-free survival (RFS) was significantly correlated with higher GPC3 mRNA expression. <i>Conclusions</i>: Our study proposes that GPC3 is a promising breast cancer subtype-specific biomarker. Moreover, GPC3 may have the potential to be a molecular target for the development of new therapeutics for specific subtypes of breast cancer.
first_indexed 2024-03-09T11:45:58Z
format Article
id doaj.art-e8ea7f14baa94ec99b4b21a34787c00f
institution Directory Open Access Journal
issn 1010-660X
1648-9144
language English
last_indexed 2024-03-09T11:45:58Z
publishDate 2022-12-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj.art-e8ea7f14baa94ec99b4b21a34787c00f2023-11-30T23:24:09ZengMDPI AGMedicina1010-660X1648-91442022-12-015918610.3390/medicina59010086Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast CancerFatemah OFO Alshammari0Anas O. Satari1Ahmed S. Aljabali2Yanal S. Al-mahdy3Yasmeen J. Alabdallat4Yahya M. Al-sarayra5Mohammad A. Alkhojah6Abdel rahman M. Alwardat7Mansour Haddad8Sameeh A. Al-sarayreh9Yousef M. Al-saraireh10Department of Medical Laboratory Technology, Faculty of Health Sciences, The Public Authority for Applied Education and Training, Shuwaikh, Kuwait City 15432, KuwaitFaculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, JordanFaculty of Medicine, Jordan University of Science and Technology, Irbid 22110, JordanFaculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, JordanFaculty of Medicine, Hashemite University, Zarqa 13133, JordanAl-Karak Governmental Hospital, Ministry of Health, Al-Karak 11118, JordanAl-Karak Governmental Hospital, Ministry of Health, Al-Karak 11118, JordanDepartment of Internal Medicine, King Abdullah University Hospital, Irbid 22110, JordanFaculty of Pharmacy, Yarmouk University, Irbid 21163, JordanDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, JordanDepartment of Pharmacology, Faculty of Medicine, Mutah University, P.O. Box 7, Al-Karak 61710, Jordan<i>Background and Objectives</i>: breast cancer remains the most common health burden affecting females worldwide. Despite developments in breast cancer diagnostic approaches and treatment strategies, the clinical management of metastatic breast cancer remains challenging. Thus, there is a need to identify new biomarkers and novel drug targets for breast cancer diagnosis and therapy. Recently, aberrant glypican-3 (GPC3) expression in cancers has gained considerable interest in cancer research. The studies, however, have yielded contradictory results about GPC3 expression in breast cancer. Therefore, the current study aims to analyse GPC3 expression across a large panel of different breast cancer subtypes. <i>Materials and Methods</i>: GPC3 expression was immunohistochemically evaluated in 230 breast cancer patients along with eight normal tissues and its associations to clinical and demographic characteristics, as well as immunohistochemical biomarkers for breast cancer. Moreover, a public database consisting of breast cancer patients’ survival data and GPC3 gene expression information was used to assess the prognostic value of GPC3 in the survival of breast cancer patients. <i>Results</i>: GPC3 expression was only characterised in 7.5% of different histological breast cancer subtypes. None of the normal breast tissues displayed GPC3 expression. Interestingly, all cases of Paget’s disease, as well as 42.9% of intraductal and 16.7% of mucinous carcinomas were found to have GPC3 expression, where it was able to significantly discriminate Paget’s disease and intraductal carcinoma from other breast cancer subtypes. Importantly, GPC3 expression was found more often in tumours that tested positive for the expression of hormone receptors and human epidermal growth factor receptor 2 (HER2), indicating more favourable histological subtypes of breast cancer. Consequently, longer relapse-free survival (RFS) was significantly correlated with higher GPC3 mRNA expression. <i>Conclusions</i>: Our study proposes that GPC3 is a promising breast cancer subtype-specific biomarker. Moreover, GPC3 may have the potential to be a molecular target for the development of new therapeutics for specific subtypes of breast cancer.https://www.mdpi.com/1648-9144/59/1/86biomarkerbreast cancerglypican-3immunohistochemistryprognosis
spellingShingle Fatemah OFO Alshammari
Anas O. Satari
Ahmed S. Aljabali
Yanal S. Al-mahdy
Yasmeen J. Alabdallat
Yahya M. Al-sarayra
Mohammad A. Alkhojah
Abdel rahman M. Alwardat
Mansour Haddad
Sameeh A. Al-sarayreh
Yousef M. Al-saraireh
Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
Medicina
biomarker
breast cancer
glypican-3
immunohistochemistry
prognosis
title Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
title_full Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
title_fullStr Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
title_full_unstemmed Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
title_short Glypican-3 Differentiates Intraductal Carcinoma and Paget’s Disease from Other Types of Breast Cancer
title_sort glypican 3 differentiates intraductal carcinoma and paget s disease from other types of breast cancer
topic biomarker
breast cancer
glypican-3
immunohistochemistry
prognosis
url https://www.mdpi.com/1648-9144/59/1/86
work_keys_str_mv AT fatemahofoalshammari glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT anasosatari glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT ahmedsaljabali glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT yanalsalmahdy glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT yasmeenjalabdallat glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT yahyamalsarayra glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT mohammadaalkhojah glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT abdelrahmanmalwardat glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT mansourhaddad glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT sameehaalsarayreh glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer
AT yousefmalsaraireh glypican3differentiatesintraductalcarcinomaandpagetsdiseasefromothertypesofbreastcancer